[en] This article presents highlights from #ERSCongress 2024 from Assembly 5 (airway diseases, asthma, COPD and chronic cough) https://bit.ly/4070nNw.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Lim, Clarice X ; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria ; Dr Lim C Consultancy, Vienna, Austria ; Dr Lim C Consultancy, Singapore
Abohalaka, Reshed ; Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Wang, Ran ; North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK ; Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, UK
Sykes, Dominic L ; Respiratory Research Group, Hull York Medical School, Hull, UK ; Hull University Teaching Hospitals NHS Trust, Hull, UK
Ardesi, Francesco ; Department of Medicine and Surgery, University of Insubria, Varese, Italy ; Department of Respiratory Sciences, University of Leicester, Institute for Lung Health, NIHR Respiratory Biomedical Research Centre, Leicester, UK
Zappa, Martina ; Department of Medicine and Cardiopulmonary Rehabilitation, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy
Bonini, Matteo; Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy ; National Heart and Lung Institute, Imperial College London, London, UK
Braunstahl, Gert-Jan ; Department of Pulmonology, Franciscus Gasthui and Vlietland, Rotterdam, The Netherlands ; Department of Pulmonology, Erasmus University Medical Center, Rotterdam, The Netherlands
Mathioudakis, Alexander G ; North West Lung Centre, Manchester University NHS Foundation Trust, Manchester, UK ; Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, UK
Snelgrove, Robert J ; National Heart and Lung Institute, Imperial College London, London, UK
Pobeha, Pavol; Department of Respiratory Medicine and Tuberculosis, Pavol Jozef Safarik University and L. Pasteur University Hospital, Kosice, Slovakia
Ananth, Sachin; National Heart and Lung Institute, Imperial College London, London, UK ; London North West University Healthcare NHS Trust, London, UK
Schleich, Florence ; Université de Liège - ULiège > Département des Sciences de l'activité physique et de la réadaptation > Physiologie humaine et physiologie de l'effort physique
Bossios, Apostolos ; Karolinska Severe Asthma Center, Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Stockholm, Sweden ; Division for Lung and Airway Research, Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden ; Lung Laboratory, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden
Beech, Augusta ; Division of Immunology, Immunity to Infection and Respiratory Medicine, University of Manchester, Manchester, UK ; Medicines Evaluation Unit, Manchester, UK
Conflict of interest: C.X. Lim reports support for attending meetings from the Ludwig Boltzmann Society. R. Abohalaka, M. Zappa and F. Ardesi have nothing to disclose. R. Wang reports grants from NIHR Manchester BRC, Asthma and Lung UK, and an NIHR Research for Patient Benefit grant; and support for meetings from Asthma and Lung UK, British Thoracic Society, North West Lung Centre Charity, and NIHR BRC travel grants. D.L. Sykes reports honoraria and speakers\u2019 fees from AstraZeneca and Chiesi outside of the submitted work, receipt of cough monitoring devices from Hyfe Ltd for use in non-funded clinical trials outside of the submitted work; and travel grants for the ERS Congress from Action for Pulmonary Fibrosis Charity. M. Bonini reports payment or honoraria for lectures and presentations from AstraZeneca, GlaxoSmithKline, Chiesi, Lusofarmaco, Menarini and Sanofi; grants or contracts from AstraZeneca and GlaxoSmithKline outside of the submitted work; consulting fees from AstraZeneca, GlaxoSmithKline, Chiesi, Lallemand, Omron and Niox outside of the submitted work; and support for attending meetings from AstraZeneca and Sanofi. G-J. Braunstahl reports payment for lectures and presentations from Sanofi, ALK ABello and AstraZeneca outside of the submitted work. A.G. Mathioudakis reports payment for lectures from GlaxoSmithKline, stock options in Healthy Networks and nonfinancial collaboration with Verona Pharma outside of the submitted work. R.J. Snelgrove is a Wellcome Trust Senior Research Fellow in Basic Biomedical Sciences (209458/Z/17/Z). P. Pobeha reports a grant from Slovak Research and Development Agency under contract number APVV-16-0158, and VEGA 1/0220/17 and 1/0393/22 of the Ministry of Education, Slovakia; payment for lectures from Berlin-Chemie; honoraria for presentations outside of the submitted work and support for attending meetings from Chiesi, Angeliny and Philips outside of the submitted work; he holds Pfizer stock options and holds a leadership or fiduciary role in the Slovak Society of Sleep Medicine and Slovak Society of Pneumology. S. Ananth reports support from NIHR Academic Clinical Fellowship in Research Medicine, and by the NIHR Imperial Biomedical Research Centre. F. Schleich reports consulting fees from GlaxoSmithKline, AstraZeneca, Chiesi, Novartis, TEVA and Sanofi, and payment for lectures from GlaxoSmithKline, AstraZeneca, Chiesi and Sanofi outside of the submitted work. A. Bossios reports a grant from AstraZeneca paid to his institution outside of the submitted work; honoraria and lecture fees from Chiesi, GlaxoSmithKline and AstraZeneca, paid to his institution outside the submitted work; and is Head of Assembly 5 (Airway diseases, asthma, COPD, and chronic cough) of the European Respiratory Society, co-chair of the Nordic Severe Asthma Network, a member of the steering committee of SHARP (ERS severe asthma Clinical Research Collaboration) and a member of the steering committee of the Swedish National Airway Register. A. Beech is the early career representative of Assembly 5 and is a member of the early career mentorship programme of this journal.
Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med 2024; 390: 2274–2283.
Papi A, Bhatt SP, Rabe KF, et al. Dupilumab improves respiratory symptoms in patients with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial. Eur Respir J 2024; 64: Suppl. 68, PA4786.
Sunjaya AP, Edwards G, Harvey J, et al. Identification of COPD from primary care spirometry with artificial intelligence (AI) interpretation software: a retrospective, diagnostic accuracy study. Eur Respir J 2024; 64: Suppl. 68, OA1047.
Brindle K, Watkins K, Shyamalee J, et al. Finding the hidden millions: identifying undiagnosed, symptomatic COPD through lung cancer screening (the FRONTIER Programme). Eur Respir J 2024; 64: Suppl. 68, PA3014.
Chuang M-H, Chen I-W, Chen J-Y, et al. Efficacy and safety of gefapixant for chronic cough: a meta-analysis of randomised controlled trials. Eur Respir Rev 2023; 32: 220219.
Morice A, Brindle K, Pawsey S, et al. Electronic cough recording: how to better reflect the patient experience? Eur Respir J 2024; 64: Suppl. 68, PA2144.
Kum E, Guyatt G, Abdulqawi R, et al. Development of the McMaster Cough Severity Questionnaire (MCSQ) for patients with chronic cough. Eur Respir J 2024; 64: Suppl. 68, PA2136.
Busse WW, Chupp G, Corbridge T, et al. Targeting asthma remission as the next therapeutic step toward improving disease control. J Allergy Clin Immunol Pract 2024; 12: 894–903.
Hansen S, Baastrup Søndergaard M, von Bülow A, et al. Clinical response and remission in patients with severe asthma treated with biologic therapies. Chest 2024; 165: 253–266.
Gates J, Haris F, Green L, et al. Relationship between FeNO suppression and clinical remission with tezepelumab in severe asthma. Eur Respir J 2024; 64: Suppl. 68, PA1195.
Devouassoux G, Jackson DJ, Käßner FF, et al. Clinical remission in patients with severe eosinophilic asthma treated with benralizumab who were randomised to reduce their inhaled corticosteroid/formoterol dose: SHAMAL post-hoc analysis. Eur Respir J 2024; 64: Suppl. 68, PA1194.
van den Borst B, van Grimbergen I, Robberts B, et al. One-year sustained and clinically meaningful outcomes following pulmonary rehabilitation in people with difficult-to-treat or severe asthma. J Allergy Clin Immunol Pract 2024; 12: 503–505.e1.
Schleich F, Louis S, Ziant S, et al. Towards a paradigm shift in Severe Asthma Management: deep analysis of the effect of suBmaximal Aerobic training (SAMBA). Eur Respir J 2024; 64: Suppl. 68, OA4581.
Calderon AA, Dimond C, Choy DF, et al. Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD. Eur Respir Rev 2023; 32: 220144.
Liu J, Tao P, Su B, et al. IL-33’s role in NET formation and neutrophil-mediated inflammation in smoke-exposed asthma through autophagy. Eur Respir J 2024; 64: Suppl. 68, OA4672.
Andersson C, Siddhuraj P, Sandén C, et al. COPD patients display pronounced changes of IL-33 and ST2 expression in alveolar capillary phenotypes. Eur Respir J 2024; 64: Suppl. 68, OA1071.
Faiz A, Mahbub RM, Boedijono FS, et al. IL-33 expression is lower in current smokers at both transcriptomic and protein levels. Am J Respir Crit Care Med 2023; 208: 1075–1087.
Booth S, Higham A, Singh D. Chronic smoke exposure reduces epithelial IL-33 expression and barrier integrity in cell culture. Eur Respir J 2024; 64: Suppl. 68, PA890.
Abdo M, Pedersen F, Kirsten A-M, et al. Association of airway inflammation and smoking status with IL-33 level in sputum of patients with asthma or COPD. Eur Respir J 2024; 64: 2400347.
Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir Med 2021; 9: 1288–1298.
Rathnayake S, Sharma M, Brandsma C-A, et al. Cell-type specific expression of TSLP and its regulation by smoking in human airway epithelium. Eur Respir J 2024; 64: Suppl. 68, PA4381.
Di Vincenzo S, Ferraro M, Lazzara V, et al. TSLP blocking modifies cross-talk between airway epithelium and macrophages reducing macrophage activation. Eur Respir J 2024; 64: Suppl. 68, OA1968.
Singh D, Brightling CE, Rabe KF, et al. Time to first moderate or severe COPD exacerbation with tezepelumab (COURSE). Eur Respir J 2024; 64: Suppl. 68, OA2773.
Norheim KL, Nieto-Fontarigo JJ, Hvidtfeldt M, et al. Tezepelumab reduces the expression of MUC5AC in patients with asthma. Eur Respir J 2024; 64: Suppl. 68, OA3650.
Scott IC, Kovacina K, Cardner M, et al. Proof of mechanism for an inhaled anti-TSLP fragment antibody, AZD8630/ AMG104, in a phase 1 study in healthy adults and asthma patients. Eur Respir J 2024; 64: Suppl. 68, OA3652.
Strickson S, Houslay KF, Negri VA, et al. Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex. Eur Respir J 2023; 62: 2202210.
Pandya H, Guller P, Reid F, et al. FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD. Eur Respir J 2024; 64: Suppl. 68, OA1964.
Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med 2024; 391: 2337–2349.
Ramakrishanan S, Russell R, Mahmood H, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab: a double-blind, double-dummy, active-placebo randomised controlled trial (ABRA). Eur Respir J 2024; 64: Suppl. 68, RCT3716.
Rabe KF, Vogelmeier CF, Bhatt SP, et al. Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial. Eur Respir J 2024; 64: Suppl. 68, PA4785.
Porsbjerg CM, Dunican E, Lugogo NL, et al. Dupilumab reduces mucus plugging and volume: phase 4 VESTIGE trial. Eur Respir J 2024; 64: Suppl. 68, OA3649.
Kim V, Diaz A, Rheault T, et al. Ensifentrine improved symptoms and reduced moderate/severe exacerbation rate and risk in patients with COPD and significant cough and sputum. Eur Respir J 2024; 64: Suppl. 68, PA2997.
